Represents Grant table in the DB

GET /v1/grants?page%5Bnumber%5D=1405&sort=-funder_divisions
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/vnd.api+json
Vary: Accept

{
    "links": {
        "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions",
        "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-funder_divisions",
        "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-funder_divisions",
        "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-funder_divisions"
    },
    "data": [
        {
            "type": "Grant",
            "id": "8529",
            "attributes": {
                "award_id": "1R13FD007383-01",
                "title": "Western Association of Food and Drug Officials (WAFDO) Annual Educational Conference Assistance",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22680,
                        "first_name": "Suzanne",
                        "last_name": "Webb",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-07-05",
                "end_date": "2026-06-30",
                "award_amount": 25000,
                "principal_investigator": {
                    "id": 24298,
                    "first_name": "Kimberly",
                    "last_name": "Stryker",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1721,
                            "ror": "",
                            "name": "WESTERN ASSOCIATION /FOOD/DRUG OFFICIALS",
                            "address": "",
                            "city": "",
                            "state": "CO",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1721,
                    "ror": "",
                    "name": "WESTERN ASSOCIATION /FOOD/DRUG OFFICIALS",
                    "address": "",
                    "city": "",
                    "state": "CO",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Western Association for Food and Drug Officials PAR-19-306 The mission of the annual WAFDO Annual Educational Conference (AEC) is to provide a venue, either virtually or in-person, where public health field practitioners and program managers, industry leaders, and academia from across the region can interact and share ideas while receiving information on current trends and emerging issues impacting public health and safety related to human and animal food, drugs, cosmetics, and medical products. The AEC agenda typically includes presentations that will give participants an opportunity to learn about state, local, national and international perspectives on all of these important public health and consumer safety topics. The annual WAFDO Conference is one of the most comprehensive and cost effective educational opportunities in the Western region (Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, British Columbia, Alberta, Guam, Northern Mariana Islands, and Mexico) that addresses the range of current public health issues facing federal, state and local regulatory programs. WAFDO keeps the cost of the conference as low as possible in an effort to allow access to the conference to the widest range of participants. The low cost of the conference enables public health professionals from all levels of the regulatory community, industry and academia to participate. The goal and objective of this application is to successfully apply for $25,000 a year for five years (2021-2026 project period, $125,000 total award) under the FDA Support for Conferences and Scientific Meetings (PAR-19-306) announcement so that WAFDO can:  Provide a high quality, comprehensive virtual conference for its 2021 annual educational conference.  Provide financial assistance for attendees to travel to future annual educational  conferences (2022-2025) who might not otherwise be able to travel due to budget  limitations or travel restrictions.  Provide attendees with appropriate printed materials and other conference resources.  Fund conference room and audio-visual equipment costs for the conference. The 2021 WAFDO AEC will be held in a virtual environment due to the prospect of ongoing COVID gathering and travel restrictions. This application assumes that future annual conferences starting in 2022 will be able to be held in person with no COVID or travel restrictions in place. If this assumption is false, WAFDO will utilize any awarded funds to defray costs associated with additional virtual deliveries. The annual educational conference will contribute to the sharing and discussion of current human and animal food, drug, cosmetic, and medical product safety topics in order to further mutual reliance between fellow public health entities and therefore move closer to a fully integrated public health and safety system.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8530",
            "attributes": {
                "award_id": "1R21OH012253-01",
                "title": "An Innovative Approach to Improving Asthma Control for World Trade Center Rescue and Recovery Workers through Telehealth Enriched Asthma Management (WTC-TEAM)",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 24208,
                        "first_name": "JAMES",
                        "last_name": "YIIN",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-07-01",
                "end_date": "2023-06-30",
                "award_amount": 241799,
                "principal_investigator": {
                    "id": 24299,
                    "first_name": "Erin",
                    "last_name": "Thanik",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 625,
                            "ror": "https://ror.org/04a9tmd77",
                            "name": "Icahn School of Medicine at Mount Sinai",
                            "address": "",
                            "city": "",
                            "state": "NY",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 625,
                    "ror": "https://ror.org/04a9tmd77",
                    "name": "Icahn School of Medicine at Mount Sinai",
                    "address": "",
                    "city": "",
                    "state": "NY",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Asthma is prevalent among World Trade Center (WTC) rescue and recovery workers (responders). Moreover, this population exhibits poorly controlled disease with high health care utilization costs, particularly among responders affected by mental health conditions. Evidence from the general population supports that asthma self-management programs can improve asthma outcomes, including asthma control and health care utilization. However, asthma self- management is not currently part of the WTC Health Program (WTCHP). That asthma morbidity and mortality are higher in older adults compared to younger adults is particularly salient for the aging WTC cohort, underscoring the potential for asthma self- management programs to become vital to meeting the unique needs of this population.  To address this need, we developed an innovative approach to optimizing asthma care: the Telehealth Enriched Asthma Management (TEAM) program. This intervention will utilize the existing clinical infrastructure of the WTCHP, including partnering with the WTC Mental Health Program, to provide asthma self-management to enhance current asthma care. The TEAM program will also leverage the recently augmented telehealth capabilities in the WTCHP (implemented in response to the SARS-CoV-2 pandemic) by delivering a series of virtual visits to provide asthma self-management education. Within this robust telehealth and clinical infrastructure, TEAM will provide care coordinated with other components of the WTCHP— Treatment Program, Mental Health Program, smoking cessation services, and social work— via a multifactorial approach that will promote uptake and adherence. The specific aims of the TEAM program are to: 1) develop an intervention that will expand telehealth capabilities to improve asthma care; 2) collect and analyze a variety of subjective and objective asthma outcome measures to evaluate the effectiveness of the TEAM intervention; 3) evaluate current barriers to telehealth platform utililzation as well as satisfaction with virtual encounters to understand how to improve WTCHP telehealth delivery.  Our proposal is evidence-based and responds to the specific needs of those most significantly impacted by the WTC disaster. We anticipate that this program will improve asthma care for this vulnerable population, while optimizing telehealth capabilities that can be implemented for other health conditions affecting WTC responders.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8549",
            "attributes": {
                "award_id": "1I21RX003731-01",
                "title": "Feasibility of a tele-game-based exercise (Tele-exergame) program to prevent deconditioning in hospitalized COVID-19 patients",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-07-01",
                "end_date": "2023-06-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 24319,
                    "first_name": "Sarvari",
                    "last_name": "Yellapragada",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1685,
                            "ror": "",
                            "name": "MICHAEL E DEBAKEY VA MEDICAL CENTER",
                            "address": "",
                            "city": "",
                            "state": "TX",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1685,
                    "ror": "",
                    "name": "MICHAEL E DEBAKEY VA MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "TX",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Conventional face-to-face in-hospital mobility program (MP) is impractical for COVID-19 patients because of its associated risk of infection to hospital staff as well as other hospitalized patients. To address the gap, we propose a novel game-based virtually supervised (contactless) foot and ankle exercise, called Tele-Exergame, as an alternative and practical option. The primary goal of this SPiRE application is to test feasibility, acceptability, and proof of concept effectiveness of Exergame in COVID-19 patients as an alternative to conventional in-hospital MP to reduce the loss of mobility during hospitalization and decline in mental health.  Exergames are digital or web-based games that use body movement to promote physical activity and generally involve strength, balance, and flexibility exercises. The tele-exergame MP, developed by our team, uses a remotely supervised and game-based approach, which helps to increase patient motivation and engagement in a cognitively demanding exercise program. For example, the Tele-Exergame MP includes foot and ankle exercise tasks with explicit augmented visual feedback (i.e., the patient's movement controls an object on the screen, thus providing real-time visual and audio feedback that is critical for motor learning). Monitoring and feedback are achieved by using wearable sensors worn on feet. Our game-based exercise includes a wide range of safe non-weight bearing exercise tasks, suitable for bedbound patients, and is inspired by an evidence-based exercise program. A popular game (flight shooter game) that could be played either while sitting or lying in bed by rapid, alternating ankle dorsiflexion and plantarflexion will be used. The motion of foot is translated into the movement of an avatar to play the game; for example, to “shoot” targets on a screen. The sensor on the foot can quantify motor and cognitive performance (e.g., slowness, weakness, exhaustion, and working memory), defined as cognitive frailty, using a validated algorithm developed by our team. Exercises are demonstrated remotely using a tele-medicine tablet, and the movement of subjects is monitored in real-time by research staff.  To demonstrate the feasibility of Tele-Exergame MP, COVID-19 or PUI (persons under investigation) participants admitted to the MEDVAMC (n=60), with an anticipated length of stay at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. Primary outcomes include acceptability, deconditioning (cognitive-frailty), and mental health (e.g., depression and anxiety) assessed at baseline, at discharge, and at 1-month post-discharge. Secondary outcomes include adverse events (e.g., venous thromboembolism (VTE), falls, etc), instrumental activities of daily living, and community mobility, which will be assessed at baseline and at one-month post-hospital discharge.  Our main hypotheses are H1) Tele-Exergame in hospital setting is feasible with less than 15% drop out and over 70% compliance; H2) The perceived ease of use, acceptability, and benefit is high as assessed using a validated technology acceptance model survey; H3) IG has less deconditioning and better mental health outcomes compared to CG at the time of discharge; H3) At 4 weeks post-discharge, the self-reported activity of daily living (ADL) and life space (LSA) would be higher in IG compared to CG.  Impact: There is no existing contact-less in-hospital MP that is available for hospitalized COVID-19 population. If the feasibility and effectiveness of the proposed tele-exergame MP is demonstrated, it will address the current challenges for implementing in-hospital MP for COVID-19 patients and also open new avenues to deliver personalized exercise for non-COVID-19 patients with limited mobility including bedbound and hospitalized patients.",
                "keywords": [
                    "Activities of Daily Living",
                    "Address",
                    "Adherence",
                    "Adverse event",
                    "Aging",
                    "Algorithms",
                    "Ankle",
                    "Anxiety",
                    "Beds",
                    "Blood Vessels",
                    "COVID-19",
                    "COVID-19 patient",
                    "Cessation of life",
                    "Cognitive",
                    "Communities",
                    "Complex",
                    "Dropout",
                    "Drops",
                    "Effectiveness",
                    "Elderly",
                    "Equilibrium",
                    "Equipment",
                    "Exercise",
                    "Feedback",
                    "Fright",
                    "Goals",
                    "Health",
                    "Home",
                    "Hospitalization",
                    "Hospitals",
                    "Image",
                    "Infection",
                    "Inpatients",
                    "Intervention",
                    "Investigation",
                    "Lead",
                    "Leg",
                    "Length of Stay",
                    "Life",
                    "Lower Extremity",
                    "Medical center",
                    "Mental Depression",
                    "Mental Health",
                    "Modeling",
                    "Monitor",
                    "Motion",
                    "Motivation",
                    "Motor",
                    "Movement",
                    "Online Systems",
                    "Outcome",
                    "Participant",
                    "Patient Self-Report",
                    "Patients",
                    "Perception",
                    "Persons",
                    "Physical activity",
                    "Pilot Projects",
                    "Play",
                    "Population",
                    "Protocols documentation",
                    "Questionnaires",
                    "Randomized",
                    "Recovery",
                    "Research",
                    "Research Support",
                    "Risk",
                    "Series",
                    "Severity of illness",
                    "Short-Term Memory",
                    "Supervision",
                    "Surveys",
                    "Tablet Computer",
                    "Tablets",
                    "Technology",
                    "Telemedicine",
                    "Telephone",
                    "Texas",
                    "Time",
                    "Translating",
                    "Veterans",
                    "Visual",
                    "Work",
                    "acceptability and feasibility",
                    "base",
                    "cognitive performance",
                    "comorbidity",
                    "deconditioning",
                    "design",
                    "digital",
                    "disability",
                    "eligible participant",
                    "evidence base",
                    "exercise intensity",
                    "exercise program",
                    "exergame",
                    "exhaustion",
                    "falls",
                    "feasibility testing",
                    "flexibility",
                    "foot",
                    "frailty",
                    "functional decline",
                    "improved",
                    "improved mobility",
                    "infection risk",
                    "innovation",
                    "instrumental activity of daily living",
                    "meter",
                    "motor learning",
                    "novel",
                    "patient population",
                    "prevent",
                    "primary outcome",
                    "programs",
                    "psychologic",
                    "recruit",
                    "secondary outcome",
                    "sensor",
                    "standard of care",
                    "venous thromboembolism",
                    "virtual",
                    "visual feedback",
                    "wearable sensor technology"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8552",
            "attributes": {
                "award_id": "2U60OH009855-11",
                "title": "Minnesota Occupational Health and Safety Surveillance Program",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22791,
                        "first_name": "Linda",
                        "last_name": "West",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-07-01",
                "end_date": "2026-06-30",
                "award_amount": 160000,
                "principal_investigator": {
                    "id": 24321,
                    "first_name": "Erik",
                    "last_name": "Zabel",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1722,
                            "ror": "",
                            "name": "MINNESOTA STATE DEPT OF HEALTH",
                            "address": "",
                            "city": "",
                            "state": "MN",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1722,
                    "ror": "",
                    "name": "MINNESOTA STATE DEPT OF HEALTH",
                    "address": "",
                    "city": "",
                    "state": "MN",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "A strategic surveillance goal of the National Institute for Occupational Safety and Health is to strengthen the capacity of state health departments to conduct occupational surveillance and related prevention activities. The purpose of this project is to enhance the capacity of the Minnesota Department of Health to promote occupational health and safety through surveillance of a core set of occupational health indicators and dissemination of the findings to appropriate stakeholders for use in setting priorities for education and prevention activities. The project will expand the use of industry and occupation reporting in established datasets and will explore new sources of data in order to include previously underserved worker populations in surveillance of occupational health and safety. The major aims of this program include: (1) Collect, analyze, disseminate and utilize Minnesota data for 24 occupational health indicators (OHIs) based on criteria established by the Council of State and Territorial Epidemiologists (CSTE); (2) Collaborate with the MDH Lead and Healthy Homes Program to participate in the Adult Blood Lead Epidemiology and Surveillance (ABLES) program; (3) Advance the inclusion and use of industry and occupation information in health informatics; (4) Disseminate surveillance findings to appropriate audiences; (5) Build and maintain collaborations and partnerships to improve state surveillance activities; (6) Develop and use new data sources to address underserved worker populations, including agricultural workers, gig workers, and salon workers; (7) Evaluate the Minnesota Occupational Health and Safety Surveillance Program using CDC guidelines to continuously improve the program; (8) Assess COVID-19 outcomes and experience by industry and occupation sector by comparing risk of infection, comparing case outcomes, and studying the impact of safety measures and business closures; and (9) Measure the impact of statewide agricultural safety policies and rural mental health interventions by developing consistently trackable indicators of farm injuries and farm community mental health status.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8560",
            "attributes": {
                "award_id": "1I21HX003373-01A1",
                "title": "Optimizing Patient-Centered Routine Care at a Distance for Veterans with Chronic Conditions",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-08-01",
                "end_date": "2023-01-31",
                "award_amount": null,
                "principal_investigator": {
                    "id": 24329,
                    "first_name": "Abigail",
                    "last_name": "Baim-Lance",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1533,
                            "ror": "",
                            "name": "JAMES J PETERS VA  MEDICAL CENTER",
                            "address": "",
                            "city": "",
                            "state": "NY",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1533,
                    "ror": "",
                    "name": "JAMES J PETERS VA  MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "NY",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background: As a result of COVID-19, the VA has undergone a sizable transition to Care at a Distance in order to ensure the safe delivery of services. Components encompass expanded telehealth, distancing measures at routine face to face visits, and other practice changes. How Veterans with chronic conditions who regularly use VA healthcare experience these changes is unknown. This 18-month pilot study assesses a mixed methods approach to describe Care at a Distance for older, chronically ill Veterans, how service changes are experienced by Veterans, and how the experiences affect health management and outcomes. Significance/Impact: The unprecedented impact of COVID-19 provides an opportunity to advance novel Veteran-centered mixed methods to understand the pandemic’s effects on Veteran healthcare. Investigations can identify and test out Veteran-centered system improvements that support preparedness for future emergencies. This study aligns with VA’s strategic goals and objectives for FY2018-2024 to promote ‘customer service,’ and HSR&D’s scientific priorities to improve telehealth’s effectiveness, and to use primary care to optimize complex chronic disease management. It also aligns with ongoing activities in the Veterans Experience Office using journey mapping to understand Veteran experiences of VA care. Innovation: The proposed mixed methods pilot study is interdisciplinary, using novel methods in VA studies. By drawing upon theories and methods of medical anthropology and health services research, the pilot study is positioned to produce deep and actionable knowledge about COVID-19’s impact on Veterans and their care. Specific Aims: Aim 1: Describe components of Care at a Distance, to inform adapting an experience-based journey mapping template, which will describe how Care at a Distance affects the healthcare experiences of older Veterans with comorbidities, and their health outcomes. Aim 2: Test the feasibility and acceptability, and conduct an analysis, of embedding experienced-based journey mapping within in-depth qualitative interviews to describe Care at a Distance for older Veterans with comorbidities, and their routine care providers. Aim 3: Assess the utility of the mixed methods techniques to examine relationships among service changes, Veteran experiences, and health outcomes, incorporating chart review as a comparative and triangulating data source. Methods: The study uses a sequential design carried out at the James J. Peters VA in Bronx, NY and VA Hudson Valley Health Care in upstate, New York. In Aim 1, a documents analysis of VA Care at a Distance changes will be conducted to refine an inventory of components, key features, and their implementation. The inventory will inform an adapted experience-based journey map template and interview topic guide, and a medical chart analysis. In Aim 2, 40 Veterans will be recruited who are 65+ years old with two or more comorbidities (one being HIV or diabetes) and eligible for enrollment in the GeriPact, or HIV clinic. Interviews will use the experience-based survey mapping template to document service encounters and experiences before COVID- 19 (prior to March 2020), in the initial phase (March-May 2020), and during the Moving Forward period (June 2020-time of study). A follow-up interview will discuss feasibility and acceptability of mapping. 12 provider interviews will be conducted about implementation and Veteran experiences of Care at a Distance, and the feasibility of journey mapping. We will analyze for feasibility and acceptability, and conduct a qualitative thematic and process analysis. In Aim 3, a chart review will be performed to examine the record of health use and outcomes, and a comparative analysis will be performed between charts and the maps. Implementation/ Next Steps: Findings will be used to develop an IIR research proposal to: 1) describe Care at a Distance impact across VA facilities; and 2) test out and evaluate interventions to improve care for Veterans, particularly those aging with chronic health conditions. The VA Veteran Experience Office will partner on this study, and continuous Veteran input will be sought.",
                "keywords": [
                    "Affect",
                    "Aging",
                    "Anthropology",
                    "COVID-19",
                    "Caring",
                    "Chronic",
                    "Chronic Disease",
                    "Chronically Ill",
                    "Clinic",
                    "Complex",
                    "Consult",
                    "Data",
                    "Data Sources",
                    "Development",
                    "Diabetes Mellitus",
                    "Disease Management",
                    "Effectiveness",
                    "Eligibility Determination",
                    "Emergency Situation",
                    "Enrollment",
                    "Ensure",
                    "Environment",
                    "Equipment and supply inventories",
                    "Evaluation",
                    "Frequencies",
                    "Future",
                    "Goals",
                    "Guidelines",
                    "HIV",
                    "Health",
                    "Health Services Research",
                    "Healthcare",
                    "Intervention",
                    "Interview",
                    "Investigation",
                    "Knowledge",
                    "Maps",
                    "Measures",
                    "Medical",
                    "Medical center",
                    "Methods",
                    "New York",
                    "Outcome",
                    "Outpatients",
                    "Patient-Centered Care",
                    "Persons",
                    "Phase",
                    "Pilot Projects",
                    "Positioning Attribute",
                    "Primary Health Care",
                    "Process",
                    "Provider",
                    "Quality of Care",
                    "Readiness",
                    "Research Proposals",
                    "Services",
                    "Surveys",
                    "System",
                    "Techniques",
                    "Telephone",
                    "Testing",
                    "Time Study",
                    "To specify",
                    "Veterans",
                    "Veterans Health Administration",
                    "Visit",
                    "acceptability and feasibility",
                    "base",
                    "care delivery",
                    "care providers",
                    "comorbidity",
                    "comparative",
                    "coronavirus disease",
                    "design",
                    "experience",
                    "feasibility testing",
                    "follow-up",
                    "health care availability",
                    "health management",
                    "health record",
                    "human old age (65+)",
                    "improved",
                    "innovation",
                    "medical appointment",
                    "medical specialties",
                    "novel",
                    "pandemic disease",
                    "patient oriented",
                    "primary care services",
                    "recruit",
                    "routine care",
                    "service delivery",
                    "social",
                    "stem",
                    "telehealth",
                    "telemonitoring",
                    "theories",
                    "virtual"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8583",
            "attributes": {
                "award_id": "1U01GH002338-01",
                "title": "SICA Study: Seroepidemiological Insight into COVID-19 transmission in Africa",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-08-31",
                "end_date": "2026-08-30",
                "award_amount": 2000000,
                "principal_investigator": {
                    "id": 24355,
                    "first_name": "Rhoel David Ramos",
                    "last_name": "Dinglasan",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 158,
                            "ror": "https://ror.org/02y3ad647",
                            "name": "University of Florida",
                            "address": "",
                            "city": "",
                            "state": "FL",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 158,
                    "ror": "https://ror.org/02y3ad647",
                    "name": "University of Florida",
                    "address": "",
                    "city": "",
                    "state": "FL",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The COVID-19 pandemic has resulted in vastly different health outcomes for populations in Sub-Saharan Africa as compared to other countries with comparatively higher case numbers and deaths. The comparatively low numbers of cases and deaths reported in the Democratic Republic of Congo (DRC) and Nigeria, as well as throughout sub-Saharan Africa, are likely reflective of poor healthcare infrastructure and limited testing capacity. It is also unclear how the level of transmission of SARS-CoV-2 in urban vs. rural settings may influence COVID- 19 severity and the subsequent identification of cases by testing sites in both countries. Our overarching hypothesis is that prior exposure to related coronaviruses and other pathogens, which partition differentially in urban vs. rural communities, have resulted in significant cross-protective immunity or innate immune priming in the population, which leads to a reduced COVID-19 burden in these countries. We will leverage ongoing longitudinal cohort studies in urban and rural sites in the DRC and Nigeria, to support the characterization of: (i) the incidence of and risk factors for SARS-CoV-2 infection and COVID-19 severity, (ii) the current distribution and severity of respiratory/non-respiratory viral and non-viral pathogens as a cause of non-COVID-19 acute febrile illness, and (iii) role that exposure to syndemic pathogens have on COVID-19 severity. To this end, we propose to describe the incidence and prevalence of SARS-CoV-2 using seroepidemiology and describe factors associated with incidence and recovery (AIM1) and the epidemiology of respiratory and non-respiratory viral or parasitic pathogens viz. acute febrile illness (AFI) during the COVID-19 pandemic (AIM2). Our long-standing relationships through community engagement activities, and direct ties to the Public Health ministries as well as the Africa Centres for Disease Control allow us to obtain and convey accurate data at local resolution. We envision that this multinational surveillance project will provide much needed insight into the epidemiology of SARS-CoV-2 infection and COVID-19 disease in the DRC and Nigeria, elucidating differences in the incidence and disease outcomes across a range of urban vs. rural settings, which in turn can inform public health policy and control measures at country and regional levels.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8678",
            "attributes": {
                "award_id": "1R43IP001166-01",
                "title": "Development of Antigen-based Vertical Flow Assay for the Rapid Detection of SARS-CoV-2, Influenza A/B, and RSV",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2021-09-30",
                "end_date": "2022-09-29",
                "award_amount": 243000,
                "principal_investigator": {
                    "id": 24450,
                    "first_name": "Arunkumar",
                    "last_name": "Arumugam",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1734,
                            "ror": "",
                            "name": "AI BIOSCIENCES, INC.",
                            "address": "",
                            "city": "",
                            "state": "TX",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1734,
                    "ror": "",
                    "name": "AI BIOSCIENCES, INC.",
                    "address": "",
                    "city": "",
                    "state": "TX",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The goal of this Phase I SBIR proposal is to develop a rapid, low-cost, multiplex immunoassay for the detection of common respiratory tract pathogens, including influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in less than 15 minutes. The development of this antigen-based test will accelerate the rapid diagnosis of SARS-CoV-2 infection, along with influenza A / influenza B and RSV. Influenza A / influenza B and RSV are the other common causative agents of respiratory tract infections other than the ongoing SARS-CoV-2 pandemic. Analyses from the CDC have suggested that there could be 10 times more Coronavirus disease 2019 (COVID-19) positive cases than reported cases. 2 This is primarily due to the slow screening process as it mainly depends on the RT-PCR based testing systems. The rapid identification of SARS-CoV-2 is critical to stop the spread of the infection as it is highly contagious. Apart from SARS-CoV-2, influenza A / influenza B and RSV cause a considerable amount of infections and severe illness. Moreover, influenza A / influenza B and RSV infections show similar symptoms to that of SARS-CoV-2 infection. Differentiating SARS-CoV-2 infections with Flu or RSV is also much needed as Flu and RSV infections have better treatment options if they are diagnosed early. Rapid tests would provide a better opportunity to choose the right treatment strategy and stop the spread of the illness. We propose to develop a rapid, multiplex test for the detection of influenza A / influenza B, RSV, and SARS-CoV-2 without any complex instrumentation. Our rapid test uses immobilized antibodies on the membrane for the capturing and simultaneous qualitative detection of specific antigens for four common respiratory tract pathogens. We will use our innovatively designed sequential injection syringe (SIS) to pre-fill the reagents and disperse them sequentially into the flow-through assay cassette. The components such as the 2nd antibody conjugated with biotin, wash buffers, neutravidin-HRP, and tetramethylbenzidine (TMB) with stable hydrogen peroxide will be sequentially dispersed into the assay cassette. After completing the assay, the colored spots that develop can be viewed without any special instrumentation and can be interpreted easily. If needed, a reader can be used to further increase the sensitivity and ability to record and send test result to the physicians. This multiplex assay can be performed in less than 15 minutes in various point-of-care (POC) and low resource settings without any special training. We will demonstrate that our test can deliver rapid results with the same level of performance as singleplex tests for each pathogen using clinical specimens. We will also validate our assay method at our collaborator's lab at the Medical College of Wisconsin. We plan to achieve 100% specificity and higher sensitivity than current lateral flow assays. If successfully developed, this rapid, multiplex test will be simple to perform and inexpensive enough for all sizes of primary-care physician's offices, nursing homes, pharmacies, and community health clinics to adopt the platform.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8679",
            "attributes": {
                "award_id": "1R03HS028102-01A1",
                "title": "CHASM: Children Hospitalizations After SARS-COV-2 for MIS-C",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 24451,
                        "first_name": "Brenda",
                        "last_name": "Harding",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-09-30",
                "end_date": "2022-09-29",
                "award_amount": 99995,
                "principal_investigator": {
                    "id": 24452,
                    "first_name": "Katherine Ann Scott",
                    "last_name": "Auger",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 897,
                            "ror": "",
                            "name": "CINCINNATI CHILDRENS HOSP MED CTR",
                            "address": "",
                            "city": "",
                            "state": "OH",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [
                    {
                        "id": 12656,
                        "first_name": "Patrick",
                        "last_name": "Brady",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": [
                            {
                                "id": 587,
                                "ror": "",
                                "name": "University of Wisconsin-Milwaukee",
                                "address": "",
                                "city": "",
                                "state": "WI",
                                "zip": "",
                                "country": "United States",
                                "approved": true
                            }
                        ]
                    }
                ],
                "awardee_organization": {
                    "id": 897,
                    "ror": "",
                    "name": "CINCINNATI CHILDRENS HOSP MED CTR",
                    "address": "",
                    "city": "",
                    "state": "OH",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Overview of Project: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious condition affecting children after COVID-19 infection. MIS-C commonly results in severe critical illness and even death. We will provide an examination of MIS-C in 49 children’s hospitals throughout the United States. In this proposal, we will advance knowledge on MIS-C severity of illness as well as evaluate initial treatment regimens. We will describe differences in initial treatment decisions and their associated risk of treatment failure. The completion of this work will result in new knowledge regarding the most effective initial treatments for MIS-C. Environment: Cincinnati Children’s Hospital Medical Center (CCHMC) is the second largest pediatric recipient of funding from the NIH. Drs. Auger and Brady are members of the Division of Hospital Medicine at CCHMC. This division is among the most research-oriented pediatric hospital medicine divisions in the country with a focus on hospital quality and safety and with four faculty members currently on AHRQ grants. Both PIs receive extensive support including computers and software, biostatistical advisors, data management support, clinical research coordinators, grants management support, and discretionary funds. Drs. Auger and Brady are also a members of CCHMC’s James M. Anderson Center for Health Systems Excellence, a nationally renowned research division that focuses on assessing and improving pediatric health care delivery. This proposal additionally leverages the vast resources of the Children’s Hospital Association (CHA) and its experienced biostatistical and data analysis team. Dr. Matt Hall as the principal biostatistician at CHA has a decade-plus experience using the Pediatric Health Information System (PHIS) to ask and answer epidemiologic and comparative effectiveness research questions. He has an extensive record of collaboration with the entire research team, having coauthored over 100 publications with members of this team. Summary: This innovative proposal will generate new, significant knowledge on both the epidemiology and management of MIS-C. This critically important information is foundational for future randomized controlled trials for MIS-C treatment and for development of evidence-based treatment algorithms and pathways.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8682",
            "attributes": {
                "award_id": "1U18FD007516-01",
                "title": "Detection of SARS-CoV-2 and characterization of SARS-CoV-2 S-gene in major companion and food animals",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 24456,
                        "first_name": "Olgica",
                        "last_name": "Ceric",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-09-15",
                "end_date": "2024-08-31",
                "award_amount": 69358,
                "principal_investigator": {
                    "id": 24457,
                    "first_name": "Jianfa",
                    "last_name": "Bai",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 197,
                            "ror": "https://ror.org/05p1j8758",
                            "name": "Kansas State University",
                            "address": "",
                            "city": "",
                            "state": "KS",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 197,
                    "ror": "https://ror.org/05p1j8758",
                    "name": "Kansas State University",
                    "address": "",
                    "city": "",
                    "state": "KS",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Project Summary: SARS-CoV-2 is a major human respiratory pathogen that can cause COVID-19, a disease with symptoms similar to those caused by Influenza A (Flu A) and Influenza B (Flu B) viruses. A few major SARS-CoV-2 variants of concern (VOC) have been identified and associated with increased transmissibility in humans, including the UK variant B.1.1.7/Alpha, South Africa variant B.1.351/Beta, Japan/Brazil variant P.1/Gamma, California variants B.1.427/B.1.429/Epsilon, and India variants B.1.6.7.1/B.1.6.7.2/Delta (CDC, 2021a). SARS-CoV-2 has also been found in different animal species, including dogs, cats, tigers, lions, minks, ferrets etc. Transmission among individuals within an animal species has been reported (Halfmann et al, 2020; OIE, 2021), as well as limited reports of animal to human transmission (Hedman et al., 2021), yet more extensive studies may be needed to draw a conclusion. Both Flu A and Flu B are major human and animal respiratory pathogens, and cause symptoms sometimes difficult to differentiate from COVID-19. This proposal has three main goals: 1) Develop and validate a multiplex real-time PCR assay for detection of SARS-CoV-2, Flu A and Flu B viruses; 2) Screening animal respiratory samples submitted to KSVDL from Months 7-30 (2 years) of the grant period; and 3) Sequencing the spike protein- encoding gene (S-gene) of all SARS-CoV-2 positive samples to identify and characterize potential variants and their relationship to human strains.  From 2018-2020, Kansas State Veterinary Diagnostic Laboratory (KSVDL) received an annual average of 11,065 animal respiratory samples, including an average of 69 feline, 491 canine, 123 equine, 1,070 swine and 9,296 bovine samples for each year. All feline and canine respiratory samples and selected samples from other species received in Months 7-30 during the grant period will be tested by the multiplex SARS-CoV-2/Flu A/Flu B assay developed in the study. S-gene sequencing of all SARS-CoV-2 positive samples will be attempted with a procedure optimized in this study and results compared to major VOC strains. Full or near-full S-gene sequences will be phylogenetically analyzed to further study the variation and genetic diversity of the SARS-CoV-2 strains identified from animal species. Analysis will also reveal if strains identified within an animal species have a closer genetic relationship than strains between species. The S-gene sequences of animal- and human-derived strains will be compared to determine if animal strains have been observed in humans. Main goals include: 1) Provide comprehensive SARS-CoV-2 positive rates, for a duration of two years, from samples collected from dogs, cats, horses, cattle and pigs; 2) Identify potential SARS-CoV-2 VOC strains from positive samples; 3) Phylogenetically analyze the S-gene from all sequenceable positive samples (Ct ≤ 32) to determine genetic diversity; 4) Identify and phylogenetically analyze similarities and differences of the S-gene of animal- and human-derived SARS-CoV-2 strains.",
                "keywords": [],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "8684",
            "attributes": {
                "award_id": "1U18FD007514-01",
                "title": "Development of multiplex real-time PCR assays for differentiating SARS-CoV-2 from other respiratory and enteric pathogens",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 24456,
                        "first_name": "Olgica",
                        "last_name": "Ceric",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2021-09-15",
                "end_date": "2022-08-31",
                "award_amount": 100000,
                "principal_investigator": {
                    "id": 24459,
                    "first_name": "Udeni B. R.",
                    "last_name": "Balasuriya",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1505,
                            "ror": "",
                            "name": "LOUISIANA STATE UNIV A&M COL BATON ROUGE",
                            "address": "",
                            "city": "",
                            "state": "LA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1505,
                    "ror": "",
                    "name": "LOUISIANA STATE UNIV A&M COL BATON ROUGE",
                    "address": "",
                    "city": "",
                    "state": "LA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "There is an urgent need for developing and validating new and improved molecular and serological tests for the diagnosis of SARS-CoV-2 in companion animals (i.e., dogs and cats). It has been shown that people with COVID-19 frequently pass SARS-CoV-2 on to their pets. Cats are more susceptible to SARS-CoV-2 than dogs, and there is evidence that both species can develop COVID-19 after a natural or experimental exposure. The clinical signs of COVID-19 in cats and dogs include respiratory signs and diarrhea, which must be differentiated from feline respiratory disease complex (FRDC), canine infectious respiratory disease complex (CIRDC or commonly known as “kennel cough”), and diarrhea caused by other viruses, bacterial and parasites. Thus, rapid detection and differentiation of SARS-CoV-2 from other common viral and bacterial agents in a single specimen is critical in controlling COVID-19 and implementing appropriate public health measures. Similarly, there is an urgent need for developing highly specific and sensitive antibody detection (serological) assays to answer fundamental questions about the epidemiology and immune response to SARS-CoV-2 and aid in the implementation and evaluation of control programs. Thus, it is hypothesized that current laboratory testing for COVID- 19 in dogs and cats could be improved by developing new multiplex real-time qPCR/RT-qPCR assays for the detection and differentiation of SARS-CoV-2 in respiratory (nasal and nasopharyngeal) and fecal specimens, as well as developing a sandwich ELISA for the detection of IgM and IgG immune responses using recombinant viral proteins. To test this central hypothesis, we have two specific aims: Aim 1). Develop Multiplex Real-time PCR Assays to Detect SARS-CoV-2 and Other Respiratory and Enteric Pathogens in Dogs and Cats: The objective is to develop a series of multiplex (quadruplex) TaqMan® real-time qPCR/RT-qPCR assays using a combination of fluorescently labeled probes. All assays will be optimized using the new TaqPath 1-Step Multiplex Master Mix; and Aim 2). Develop Sandwich ELISA for the Detection of Antibodies to SARS-CoV-2 in Dog and Cat Serum Samples: To detect IgM and IgG immune response to SARS-CoV-2 in dogs and cats using recombinant nucleocapsid (N) and spike (S) proteins. In summary, multiplex real-time qPCR/RT-qPCR assays are highly sensitive and specific and will rapidly identify and distinguish dogs and cats infected with SARS-CoV-2. The development and validation of both IgM and IgG ELISA will allow identifying animals exposed to the virus. These newly developed assays will enhance the molecular and serologic diagnosis of SARS-CoV-2 in pets, and also, advance epidemiological investigations.",
                "keywords": [],
                "approved": true
            }
        }
    ],
    "meta": {
        "pagination": {
            "page": 1405,
            "pages": 1442,
            "count": 14420
        }
    }
}